Key takeaway
What This Development Means
The CJEU has dismissed the European Commission's appeal to restrict access to EFSA's 2013 guidance documents on plant protection products, reinforcing EU transparency principles and public access rights.
What was the European Commission's appeal about?
The European Commission appealed to restrict access to documents related to the EFSA's 2013 guidance on plant protection products, citing the protection of its decision-making process. However, the CJEU dismissed the appeal, emphasising the importance of transparency.
Why is the EFSA guidance document significant?
The EFSA guidance document is crucial for assessing the risks of plant protection products, particularly their impact on bees. Access to this information is vital for stakeholders to understand and influence chemical legislation and environmental protection efforts.
Source basis: https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A62022CJ0726
The European Commission's appeal to restrict access to documents related to the European Food Safety Authority's (EFSA) 2013 guidance on plant protection products has been dismissed by the Court of Justice of the European Union (CJEU). This decision, delivered on 16 January 2025, marks a significant moment in the ongoing debate over transparency and public access to EU documents.
Background Of The Case
The case originated from a request by Pollinis France, an environmental NGO, seeking access to documents concerning the EFSA's guidance on the risk assessment of plant protection products on bees. The Commission had initially refused access, citing the protection of its decision-making process under Article 4(3) of Regulation No 1049/2001. However, the General Court annulled this decision, leading to the Commission's appeal.
Court's Rationale
The CJEU upheld the General Court's decision, emphasising the importance of transparency in EU institutions. The Court noted that the Commission's decision-making process was not ongoing at the time of the request, as the revision of the guidance document was still pending. Therefore, the exception to public access was not applicable.
Implications For Public Access
This ruling reinforces the principle of openness within the EU, as outlined in Regulation No 1049/2001, which aims to provide the public with the widest possible access to documents. The decision highlights the need for EU institutions to justify any refusal of access with specific and foreseeable risks to their decision-making processes.
Impact On Chemical Legislation
The EFSA's guidance document is crucial for evaluating plant protection products, particularly concerning their impact on bees. This decision ensures that stakeholders, including environmental groups and the public, have access to information that could influence the regulation and use of such chemicals.
Future Considerations
The Commission's discretion in adopting or amending guidance documents remains, but this case sets a precedent for how transparency and public interest are balanced against institutional confidentiality. The decision may prompt a review of how EU bodies handle document access requests, especially those related to environmental and public health matters.
Related Articles

ClientEarth v European Commission Reinforces Transparency Rules On Mancozeb And Cypermethrin Decisions
ClientEarth v European Commission confirms that the Commission must justify refusals to disclose pesticide-related documents with specific evidence. While reinforcing transparency around mancozeb and cypermethrin decision-making, the ruling preserves important limits where disclosure could undermine court proceedings, signalling a more balanced but stricter application of EU access-to-documents rules.

EU Publishes Draft Plant Protection Products Labelling Regulation
The EU invites feedback on the updated plant protection product labelling regulation until 3 February 2025. Share your views to shape the final regulation.

German Agriculture Group Challenges EU Decision On Fluopyram Approval Extension
German agriculture alliance challenges EU decision on Fluopyram approval extension, citing regulatory violations and health risks.
